Skip to main content
KRRO
NASDAQ Life Sciences

Novo Nordisk Ends $530M RNA-Editing Pact; Korro Bio Falls 11%

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$14.86
Mkt Cap
$218.823M
52W Low
$5.204
52W High
$36.79
52W Position info
186% above low
Off High info
60% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

KRRO has more than doubled off its 52-week low of $5.204 on elevated volume (1.9× avg).

Summary

Novo Nordisk gave notice on Nov. 3 that it is terminating the research collaboration and license agreement with Korro Bio, effective Feb. 1, 2027. The 2024 deal had made Korro eligible for up to $530 million in upfront, development and commercial milestone payments across two undisclosed cardiometabolic targets, and Novo declined to nominate the second target. This follows the 8-K filed today disclosing the termination and the November 2025 12-month pause that came with a 34% workforce cut — the partnership has been unwinding for a year. Shares fell 11% to $14.88 midday Thursday, though they remain up about 86% year to date. The loss of a large-pharma partner removes external validation and milestone cash, but the balance sheet is not the immediate problem: $124.8 million in cash and securities at Sept. 30 funds operations into the second half of 2028, and the Q3 net loss narrowed to $17.5 million, or 98 cents a share, from $18.1 million, or $1.92, a year earlier. The company's own pipeline — KRRO-121 in the Phase 1/2 ANCHOR trial and preclinical KRRO-111 data — now carries the story alone.

At the time of this announcement, KRRO was trading at $14.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.8M. The 52-week trading range was $5.20 to $36.79. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

KRRO - Latest Insights

KRRO
Nov 05, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.29
Real-time Price: $12.19 info
Change: -$4.10 (-25%) info
Market Cap: $167.316M info
KRRO
Oct 26, 2026, 6:37 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $12.02
Real-time Price: $12.19 info
Change: +$0.170 (+1%) info
Market Cap: $167.316M info
KRRO
Oct 22, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $12.19 info
Change: +$2.84 (+30%) info
Market Cap: $167.316M info
KRRO
Oct 22, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $12.19 info
Change: +$2.84 (+30%) info
Market Cap: $167.316M info
KRRO
Oct 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $9.97
Real-time Price: $12.19 info
Change: +$2.22 (+22%) info
Market Cap: $167.316M info